To the Editor-in-Chief:
Every year, about 4000 Australian residents perform Hajj in Makkah, Saudi Arabia. Recommended preventative measures are available but compliance varies ( Table 1) . 1 A quadrivalent (ACYW) meningococcal vaccine administered ≥10 days before travel is a compulsory visa requirement for all travellers. A conjugate or a polysaccharide vaccine is acceptable but the former provides protection for 5 years compared with 3 years for polysaccharide vaccines. 2 Currently, three brands of conjugated vaccines (Nimenrix ® , Menveo ® and Menactra ® ), but no polysaccharide vaccine, are available in Australia. In 2018, Nimenrix ® replaced the Hib-MenC vaccine at 12 months of age on the national immunisation program (NIP) and hence funded for eligible individuals. There may be some brand-specific immune interference with other vaccines: for example, Menactra ® should not be coadministered with pneumococcal conjugate vaccine, but be given at least 4 weeks later, and administering tetanus, low-dose diphtheria and acellular pertussis (Tdap) vaccine 3-4 weeks after (not before) Nimenrix ® has the advantage of an enhanced tetanus immunity. 3 Influenza vaccine is strongly recommended for Hajj pilgrims and the uptake among Australian pilgrims has improved in recent years to about 80%. 1 Currently, quadrivalent influenza vaccines (including both lineages of influenza B) are available in Australia for individuals aged <65 years, two higher-immunogenicity trivalent influenza vaccines (one 'high-dose' vaccine and another adjuvant) are funded under the NIP for adults aged ≥65 years.
It is also advised that pilgrims remain up-to-date with other routine vaccines, including measles, pertussis and hepatitis B-containing vaccines. Travellers born in Australia before 1966 are likely to have natural immunity to measles, and those born after 1965 should have documented evidence of two doses of a measles-containing vaccine either as MMR (measles-mumpsrubella) or MMRV (along with varicella, if age-eligible). There is considerable risk of pertussis among Hajj pilgrims. 4 In Australia, Tdap vaccines are available free at age 10-15 years and for pregnant women from 28 weeks of gestation, and recommended for elderly adults if not received in the previous 10 years. Any pilgrim unsure of their Tdap vaccination status should get vaccinated. Hepatitis B risks at Hajj include sharing of razors to shave heads by men to mark the conclusion of Hajj. The NIP has a 4-dose schedule of hepatitis B at birth, 2, 4 and 6 months of age, but Australianborn adults and migrants may not be immunised, vaccination should be considered. Some Hajj pilgrims receive hepatitis A and typhoid vaccines, although the actual benefit remains unclear.
There is slow sustained transmission of MERS-CoV in Saudi Arabia but no Hajj-associated cases reported, with only 28% Australian pilgrims being aware of the disease and some even engaging in high-risk activities (2% reported camel exposure). 5 The Australian Department of Health alerts travellers about MERS-through an information card for travellers about MERS (available from: http://www.health.gov.au) with the advice to avoid close contact with sick people and animals, avoid raw camel products, practise hand washing, report and seek medical help if become symptomatic after Hajj.
In Australia, tour operators play an important role in advising pilgrims on preventative health measures. Pilgrims who obtain pre-travel health advice from travel agents are twice as likely to be aware of official health advice, receive recommended vaccines before travel and use hand sanitisers, and three times as likely to wash hands after touching an ill person compared with those who seek advice from GPs. It is important that Hajj pilgrims are aware of various health hazards; know about the availability of vaccines and other simple preventive measures (e.g. hand hygiene). Well-informed tour group leaders can play an important role in pre-travel health education.
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